Sanofi reported stronger-than-expected earnings growth for the third quarter of 2024, driven by an earlier start to the vaccination season and robust sales of its products. The French pharmaceutical company posted earnings per share (EPS) of $1.57, surpassing analysts' estimates of $1.39, while revenues reached $14.77 billion, exceeding the forecast of $13.94 billion. The company's profit growth was particularly bolstered by strong demand for its seasonal vaccines and the performance of Dupixent, its leading drug for skin and asthma treatments. Additionally, sales for Beyfortus, a respiratory syncytial virus (RSV) antibody, contributed to the positive results. Following the announcement, Sanofi's shares rose by 2.3%, reflecting investor confidence in the company's performance and outlook.